Source: Ophthalmology
Area: News
A recent cohort study of Medicare patients concluded that vascular endothelial growth factor (VEGF)-inhibiting drugs for age-related macular degeneration (AMD) were not associated with an increased risk of stroke. However, the population-level safety of the individual VEGF inhibitors remains an important public health issue.
To investigate further, researchers conducted a population-based time series analysis evaluating whether stroke rates among patients with retinal disease were influenced by the rapid and sequential uptakes of bevacizumab and ranibizumab for AMD,
Canadian health care linked databases were used to identify all patients aged 66 years or older with retinal disease in the previous 5 years (2002 and 2010, n = 116,388). A secondary analysis evaluated patients who had undergone photodynamic therapy (PDT) within the preceding year (n = 10,059). The primary outcome was hospitalisations for ischemic stroke and was compared across three ...
Uncategorized